uniQure (QURE) Expected to Release Quarterly Earnings on Wednesday

Key Points

• uniQure is expected to report Q3 2026 results before the market opens on Wednesday, November 4. Analysts forecast a loss of $0.9152 per share and revenue of $6.17 million; the earnings call is scheduled for 8:30 a.m. ET.
• The company’s previous quarter fell short of earnings expectations, reporting a $1.22-per-share loss versus the $0.82 consensus estimate, though revenue of $5.84 million exceeded forecasts.
• Analyst sentiment remains mixed but leans positive, with a “Moderate Buy” consensus rating and an average price target of $53.25, compared with shares recently trading at $25.30.

uniQure (NASDAQ:QURE - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.9152) per share and revenue of $6.17 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The business had revenue of $5.84 million during the quarter, compared to analysts' expectations of $5.45 million. During the same quarter in the previous year, the business earned ($0.69) EPS. On average, analysts expect uniQure to post ($3.82) EPS for the current fiscal year and ($3.55) EPS for the next fiscal year.

uniQure Stock Performance

NASDAQ QURE opened at $25.30 on Friday. The firm has a market cap of $1.76 billion, a P/E ratio of -6.31 and a beta of 1.06. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The company's 50 day moving average is $35.04 and its 200-day moving average is $29.66. uniQure has a 12-month low of $8.73 and a 12-month high of $69.99.

Wall Street Analyst Weigh In

QURE has been the topic of a number of analyst reports. Wells Fargo & Company reissued an "overweight" rating and set a $75.00 target price on shares of uniQure in a report on Tuesday, September 29th. Barclays lowered uniQure from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $60.00 to $28.00 in a report on Monday, October 5th. Wolfe Research upgraded uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a research report on Wednesday, July 29th. Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, September 5th. Finally, The Goldman Sachs Group decreased their price objective on uniQure from $46.00 to $31.00 and set a "neutral" rating on the stock in a research note on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $53.25.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.